首页|miRNAs对食管癌发生发展的影响及中医药的干预作用

miRNAs对食管癌发生发展的影响及中医药的干预作用

扫码查看
食管癌是常见的上消化道恶性肿瘤,在我国食管癌的总患病数和死亡数占全球的一半,极大地加重了我国癌症防治及医疗保障体系的负担.食管癌早期发病隐匿、不易察觉,导致多数患者在确诊时已处于中晚期,不利于治疗和预后.微小RNA(miRNAs)作为新型生物标志物,在肿瘤的诊断、病情监测和预后评估中发挥着重要作用.近年研究表明,miRNAs在食管癌微环境的形成,放化疗抵抗,肿瘤细胞增殖、凋亡、侵袭、自噬等过程中扮演着抑癌基因和抗癌基因的双重角色,是食管癌潜在的干预靶点,具有较高的研究价值和意义.但miRNAs在食管癌进展中的作用机制尚不明确,限制其作为肿瘤标志物应用于食管癌的临床诊断、治疗和预后.基于此,文章就miRNAs在食管癌发生发展中的双重调控机制及中医药干预研究进行系统综述,旨在明确miRNAs如何影响食管癌的发生与发展及潜在治疗策略,以期为食管癌的临床防治提供新思路.
Impact of miRNAs on the development of esophageal cancer and intervention role of traditional Chinese medicine
Esophageal cancer is a common upper gastrointestinal malignant tumor.The total number of cases and deaths of esophageal cancer accounts for half of the world,greatly increasing the burden of cancer prevention and medical insurance in China.The early onset of esophageal cancer is insidious and hard to detect,resulting in most patients being in the middle and advanced stages at the time of diagnosis,and dalayed the treatment and unsatisfactory prognosis.As novel biomarkers,microRNAs(miRNAs)play an important role in tumor diagnosis,disease monitoring,and prognosis assessment.Recent studies have shown that miRNAs play the dual roles of tumor suppressor genes and anti-cancer genes in the formation of esophageal cancer microenvironment,radiotherapy and chemotherapy resistance,cancer cell proliferation,apoptosis,invasion,and autophagy,etc.,and are also potential intervention targets for esophageal cancer.However,the mechanism of miRNAs in the progression of esophageal cancer remains unclear,which limits their application as tumor markers in clinical diagnosis,treatment and prognosis of esophageal cancer.This paper systematically reviewed the dual regulatory mechanism of miRNAs in the occurrence and development of esophageal cancer and intervention with traditional Chinese medicine.

esophageal cancermiRNAsregulatory mechanismtumor celltraditional Chinese medicine

李晨辉、彭孟凡、孔小莉、白明、苗明三

展开 >

河南中医药大学,郑州 450046

黄淮学院,河南 驻马店 463000

食管癌 miRNAs 调控机制 肿瘤细胞 中医药

岐黄学者河南省重大公益专项国家中医药管理局联合开放课题

国中医药人教函2022-6201300310100GZY-KJS-2022-040-1

2024

中南药学
湖南省药学会

中南药学

CSTPCD
影响因子:0.736
ISSN:1672-2981
年,卷(期):2024.22(2)
  • 38